Publications by authors named "C Gerke"

Scale-up isolation of (+)-(5)-(8)-(14)-mycothiazole () from Vanuatu specimens of to semisynthesize (+)-(5)-(8)-8--acetyl-(14)-mycothiazole () revealed a new diastereomer, (-)-(5)-(8)-(14)-mycothiazole (). The structure of was determined using HRMS, NMR, and comparing optical rotation to (-)-(5)-(8)-(14)-mycothiazole () and . The maximum tolerated dose of in mice was 0.

View Article and Find Full Text PDF

Human leucocyte antigen class I (HLA-I) molecules play a central role for both NK and T-cell responses that prevent serious human cytomegalovirus (HCMV) disease. To create opportunities for viral spread, several HCMV-encoded immunoevasins employ diverse strategies to target HLA-I. Among these, the glycoprotein US10 is so far insufficiently studied.

View Article and Find Full Text PDF

In the early COVID-19 pandemic with urgent need for countermeasures, we aimed at developing a replicating viral vaccine using the highly efficacious measles vaccine as vector, a promising technology with prior clinical proof of concept. Building on our successful pre-clinical development of a measles virus (MV)-based vaccine candidate against the related SARS-CoV, we evaluated several recombinant MV expressing codon-optimized SARS-CoV-2 spike glycoprotein. Candidate V591 expressing a prefusion-stabilized spike through introduction of two proline residues in HR1 hinge loop, together with deleted S1/S2 furin cleavage site and additional inactivation of the endoplasmic reticulum retrieval signal, was the most potent in eliciting neutralizing antibodies in mice.

View Article and Find Full Text PDF
Article Synopsis
  • SARS-CoV-2, which emerged in late 2019, has caused a global pandemic, with 34 vaccines approved and about 67% of the world vaccinated, yet new infections and variants still pose challenges.
  • Researchers evaluated a new measles virus-vectored vaccine (V591) designed to target the SARS-CoV-2 spike protein in an African green monkey model, demonstrating strong immune responses pre-challenge.
  • V591-vaccinated monkeys showed reduced viral loads and earlier cessation of virus shedding after exposure to SARS-CoV-2, leading to a lower disease burden in their lungs compared to those given a control vaccine.
View Article and Find Full Text PDF

Recurrent, ancient arms races between viruses and hosts have shaped both host immunological defense strategies as well as viral countermeasures. One such battle is waged by the glycoprotein US11 encoded by the persisting human cytomegalovirus. US11 mediates degradation of major histocompatibility class I (MHC-I) molecules to prevent CD8+ T-cell activation.

View Article and Find Full Text PDF